Shares of Nivalis Therapeutics, Inc. (NASDAQ:ALPN) have earned an average rating of “Hold” from the ten analysts that are covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, four have given a hold recommendation, three have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $7.21.
A number of brokerages have recently issued reports on ALPN. Ladenburg Thalmann Financial Services began coverage on shares of Nivalis Therapeutics in a research report on Thursday, July 27th. They issued a “buy” rating and a $17.00 price objective on the stock. ValuEngine downgraded shares of Nivalis Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, August 2nd. Zacks Investment Research raised shares of Nivalis Therapeutics from a “hold” rating to a “buy” rating and set a $3.00 price objective on the stock in a research report on Wednesday, April 19th. Finally, Cowen and Company reaffirmed a “hold” rating on shares of Nivalis Therapeutics in a research report on Wednesday, April 19th.
Shares of Nivalis Therapeutics (ALPN) traded down 0.21% on Tuesday, hitting $9.48. 75,265 shares of the stock traded hands. The stock’s 50 day moving average price is $9.29 and its 200 day moving average price is $9.80. The stock’s market cap is $12.70 million. Nivalis Therapeutics has a 52-week low of $8.00 and a 52-week high of $37.40.
In related news, insider Value Fund L. P. Biotechnology bought 17,806 shares of the company’s stock in a transaction on Tuesday, June 20th. The shares were bought at an average price of $2.25 per share, with a total value of $40,063.50. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Value Fund L. P. Biotechnology bought 78,858 shares of the company’s stock in a transaction on Friday, May 19th. The shares were bought at an average cost of $2.30 per share, for a total transaction of $181,373.40. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 397,998 shares of company stock worth $913,454. 3.00% of the stock is owned by insiders.
About Nivalis Therapeutics
Nivalis Therapeutics, Inc is a pharmaceutical company. The Company focuses on the discovery and development of product candidates for patients with cystic fibrosis (CF). Its drug candidate portfolio consists of multiple compounds, which are designed for oral, intravenous (IV) or inhaled administration.
Receive News & Ratings for Nivalis Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nivalis Therapeutics Inc. and related companies with our FREE daily email newsletter.